Labcorp (LH) investor relations material

Strategic vision and market positioning

• Focus on leading in specialty testing (oncology, neurology, autoimmune, women's health) and being the partner of choice for health systems and pharma, leveraging global scale, scientific innovation, and advanced technology.

• Emphasis on personalized health solutions to reduce healthcare costs, with diagnostics as a key enabler, and capitalizing on healthcare trends like aging population and consumer engagement.

• Integrated diagnostics and biopharma laboratory services create a virtuous cycle of innovation, supporting drug development and real-world care.

• Technology and AI are central to transforming operations, enhancing customer experience, and driving productivity, with AI and robotics shaping the future.

• Strong partnerships with major pharma, health systems, and providers, supported by a robust acquisition strategy and high customer trust.

Diagnostics business highlights

• Diagnostics revenue projected to grow from $9.4B in 2023 to $11.5B in 2026, a 7% CAGR, driven by volume growth, specialty testing, and M&A.

• Specialty diagnostics (oncology, neurology, autoimmune, women's health) growing three times faster than the broader market, with $2B annual revenue and strong double-digit CAGRs.

• Over 90% of U.S. lives covered, 9,200+ patient access points, and 175M+ patient interactions annually.

• Technology and AI enhance patient/provider experiences, optimize logistics, and support diagnostics.

Biopharma laboratory services (BLS) highlights

• BLS revenue expected to grow from $2.8B in 2023 to $3.3B in 2026, a 6% CAGR, supported by strong R&D pipelines and increasing trial complexity.

• 85% of FDA drug and therapeutic approvals supported; global reach with 100+ countries served.

• Integrated platform offers end-to-end clinical trial support, leveraging data and patient access for decentralized and hybrid trials.